Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Microbix Biosystms ( (TSE:MBX) ) is now available.
Microbix Biosystems Inc. announced the scheduled release of its Q1 fiscal 2025 financial results on February 13, 2025. The company will host a webinar discussion with its executives to review these results, providing an opportunity for investors and shareholders to engage. This announcement highlights Microbix’s commitment to transparency and maintaining communication with its stakeholders, potentially impacting its market positioning and investor relations positively.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company specializing in creating proprietary biological products for human health. It focuses on enabling the worldwide commercialization of diagnostic assays through critical ingredients and devices for the global diagnostics industry, such as antigens for immunoassays and laboratory quality assessment products (QAPs™). The company also develops other proprietary products like Kinlytic® urokinase and reagents for molecular diagnostic testing. Microbix operates internationally with a presence in over 30 countries and is accredited by various health authorities.
YTD Price Performance: 25.00%
Average Trading Volume: 143,309
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$67.24M
For a thorough assessment of MBX stock, go to TipRanks’ Stock Analysis page.
